PH12021552428A1 - Liposomal formulations, and methods of using and preparing thereof - Google Patents

Liposomal formulations, and methods of using and preparing thereof

Info

Publication number
PH12021552428A1
PH12021552428A1 PH1/2021/552428A PH12021552428A PH12021552428A1 PH 12021552428 A1 PH12021552428 A1 PH 12021552428A1 PH 12021552428 A PH12021552428 A PH 12021552428A PH 12021552428 A1 PH12021552428 A1 PH 12021552428A1
Authority
PH
Philippines
Prior art keywords
preparing
methods
compositions
phosphorylated
liposomal formulations
Prior art date
Application number
PH1/2021/552428A
Other languages
English (en)
Inventor
Samuel Eric Greenberg
Agnes Rafalko
Teppei Shirakura
Original Assignee
Glycomine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine Inc filed Critical Glycomine Inc
Publication of PH12021552428A1 publication Critical patent/PH12021552428A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2021/552428A 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof PH12021552428A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (1)

Publication Number Publication Date
PH12021552428A1 true PH12021552428A1 (en) 2022-07-11

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552428A PH12021552428A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Country Status (19)

Country Link
US (1) US12691131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946365A4 (cg-RX-API-DMAC7.html)
JP (1) JP7583741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210143906A (cg-RX-API-DMAC7.html)
CN (1) CN113873998A (cg-RX-API-DMAC7.html)
AR (1) AR119705A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020252005B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134828A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002512A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014274A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192663A1 (cg-RX-API-DMAC7.html)
IL (1) IL286713B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011876A (cg-RX-API-DMAC7.html)
PE (1) PE20212366A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552428A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110623PA (cg-RX-API-DMAC7.html)
TW (1) TWI906214B (cg-RX-API-DMAC7.html)
WO (1) WO2020205530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
US20250248939A1 (en) * 2022-04-18 2025-08-07 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO2000051565A1 (en) 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7011845B2 (en) 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
CA2471960A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation
EP1478341A4 (en) 2002-01-09 2009-05-20 Transave Inc EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES
WO2004103510A2 (en) 2003-05-14 2004-12-02 The Regents Of The University Of Colorado Methods and apparatus using electrostatic atomization to form liquid vesicles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
JP2008518925A (ja) 2004-10-29 2008-06-05 ネオファーム、インコーポレイティッド リポソーム製剤の製造プロセス
FR2897779B1 (fr) 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
CA2761916A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
WO2010138550A1 (en) 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110257233A1 (en) 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
EP2598120B1 (en) 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
WO2014063757A1 (en) 2012-10-26 2014-05-01 Universiteit Leiden Delivery methods
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
ES3026657T3 (en) 2013-09-16 2025-06-11 Glycomine Inc Pharmaceutical preparation of carbohydrates for therapeutic use
US20150132369A1 (en) 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN107207614B (zh) 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
US20170165374A1 (en) 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Also Published As

Publication number Publication date
TWI906214B (zh) 2025-12-01
EA202192663A1 (ru) 2022-03-01
KR20210143906A (ko) 2021-11-29
JP2022527638A (ja) 2022-06-02
IL286713B2 (en) 2025-07-01
SG11202110623PA (en) 2021-10-28
AU2020252005B2 (en) 2025-11-27
US12691131B2 (en) 2026-07-28
CN113873998A (zh) 2021-12-31
EP3946365A4 (en) 2023-04-19
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
TW202102231A (zh) 2021-01-16
JP7583741B2 (ja) 2024-11-14
EP3946365A1 (en) 2022-02-09
BR112021019593A2 (pt) 2021-12-14
US20220184107A1 (en) 2022-06-16
AU2020252005A1 (en) 2021-11-04
WO2020205530A1 (en) 2020-10-08
CA3134828A1 (en) 2020-10-08
CO2021014274A2 (es) 2022-01-17
MX2021011876A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
MX2024001210A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
PH12020550258A1 (en) Trispecific proteins and methods of use
MY209708A (en) Niraparib formulations
BR112021020011A2 (pt) Preparação e armazenamento de formulações de rna lipossômico adequadas para terapia
CO2021014274A2 (es) Formulaciones liposomales y métodos de uso y preparación de las mismas
EP4681775A3 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MY199968A (en) Formulations of an lsd1 inhibitor
SG10201908354VA (en) Riluzole prodrugs and their use
MX2018013995A (es) Células troncales mesenquimales y uso de las mismas para el tratamiento de lesiones musculares y enfermedades asociadas al músculo.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
HK1252778A1 (zh) 细胞扩增方法和治疗组合物
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
WO2015076717A3 (en) Mscs in the treatment of cardiac disorders